Herpes Zoster and Postherpetic Neuralgia: Practical Consideration for Prevention and Treatment.
10.3344/kjp.2015.28.3.177
- Author:
Young Hoon JEON
1
Author Information
1. Department of Anesthesiology and Pain Medicine, School of Dentistry, Kyungpook National University, Daegu, Korea. jeon68@knu.ac.kr
- Publication Type:Review
- Keywords:
Analgesic;
Herpes zoster;
Intervention;
Postherpetic neuralgia;
Vaccination;
Varicella zoster virus
- MeSH:
Analgesics, Opioid;
Anticonvulsants;
Antidepressive Agents;
Antiviral Agents;
Capsaicin;
Early Diagnosis;
Exanthema;
Ganglia, Sensory;
Herpes Zoster*;
Herpesvirus 3, Human;
Immunity, Cellular;
Incidence;
Lidocaine;
Neuralgia, Postherpetic*;
Risk Factors;
Vaccination
- From:The Korean Journal of Pain
2015;28(3):177-184
- CountryRepublic of Korea
- Language:English
-
Abstract:
Herpes zoster (HZ) is a transient disease caused by the reactivation of latent varicella zoster virus (VZV) in spinal or cranial sensory ganglia. It is characterized by a painful rash in the affected dermatome. Postherpetic neuralgia (PHN) is the most troublesome side effect associated with HZ. However, PHN is often resistant to current analgesic treatments such as antidepressants, anticonvulsants, opioids, and topical agents including lidocaine patches and capsaicin cream and can persist for several years. The risk factors for reactivation of HZ include advanced age and compromised cell-mediated immunity (CMI). Early diagnosis and treatment with antiviral agents plus intervention treatments is believed to shorten the duration and severity of acute HZ and reduce the risk of PHN. Prophylactic vaccination against VZV can be the best option to prevent or reduce the incidence of HZ and PHN. This review focuses on the pathophysiology, clinical features, and management of HZ and PHN, as well as the efficacy of the HZ vaccine.
